BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 8698850)

  • 1. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
    Wei X; McLeod HL; McMurrough J; Gonzalez FJ; Fernandez-Salguero P
    J Clin Invest; 1996 Aug; 98(3):610-5. PubMed ID: 8698850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
    van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
    Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
    Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
    van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
    Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea.
    Meinsma R; Fernandez-Salguero P; Van Kuilenburg AB; Van Gennip AH; Gonzalez FJ
    DNA Cell Biol; 1995 Jan; 14(1):1-6. PubMed ID: 7832988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of dihydropyrimidine dehydrogenase deficiency in a neonate with thymine-uraciluria.
    Au KM; Lai CK; Yuen YP; Shek CC; Lam CW; Chan AY
    Hong Kong Med J; 2003 Apr; 9(2):130-2. PubMed ID: 12668826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Known variant DPYD alleles do not explain DPD deficiency in cancer patients.
    Collie-Duguid ES; Etienne MC; Milano G; McLeod HL
    Pharmacogenetics; 2000 Apr; 10(3):217-23. PubMed ID: 10803677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
    Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the human dihydropyrimidine dehydrogenase gene.
    Wei X; Elizondo G; Sapone A; McLeod HL; Raunio H; Fernandez-Salguero P; Gonzalez FJ
    Genomics; 1998 Aug; 51(3):391-400. PubMed ID: 9721209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism.
    Gross E; Seck K; Neubauer S; Mayr J; Hellebrand H; Ratanaphan A; Lutz V; Stockinger H; Kiechle M
    Int J Oncol; 2003 Feb; 22(2):325-32. PubMed ID: 12527930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of correlation between phenotype and genotype for the polymorphically expressed dihydropyrimidine dehydrogenase in a family of Pakistani origin.
    Fernandez-Salguero PM; Sapone A; Wei X; Holt JR; Jones S; Idle JR; Gonzalez FJ
    Pharmacogenetics; 1997 Apr; 7(2):161-3. PubMed ID: 9170156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
    Ezzeldin H; Johnson MR; Okamoto Y; Diasio R
    Clin Cancer Res; 2003 Aug; 9(8):3021-8. PubMed ID: 12912951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.
    Johnson MR; Wang K; Diasio RB
    Clin Cancer Res; 2002 Mar; 8(3):768-74. PubMed ID: 11895907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.
    Mattison LK; Soong R; Diasio RB
    Pharmacogenomics; 2002 Jul; 3(4):485-92. PubMed ID: 12164772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography.
    Fischer J; Schwab M; Eichelbaum M; Zanger UM
    Genet Test; 2003; 7(2):97-105. PubMed ID: 12885330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
    Boisdron-Celle M; Capitain O; Faroux R; Borg C; Metges JP; Galais MP; Kaassis M; Bennouna J; Bouhier-Leporrier K; Francois E; Baumgaertner I; Guerin-Meyer V; Cojocarasu O; Roemer-Becuwe C; Stampfli C; Rosenfeld L; Lecompte T; Berger V; Morel A; Gamelin E
    Semin Oncol; 2017 Feb; 44(1):13-23. PubMed ID: 28395758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.
    Gardiner SJ; Begg EJ; Robinson BA
    Adverse Drug React Toxicol Rev; 2002; 21(1-2):1-16. PubMed ID: 12140902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency.
    Ezzeldin H; Okamoto Y; Johnson MR; Diasio RB
    Anal Biochem; 2002 Jul; 306(1):63-73. PubMed ID: 12069415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
    Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.